{"pmid":32447523,"title":"Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines.","text":["Harnessing the power of novel animal-free test methods for the development of COVID-19 drugs and vaccines.","The COVID-19-inducing virus, SARS-CoV2, is likely to remain a threat to human health unless efficient drugs or vaccines become available. Given the extent of the current pandemic (people in over one hundred countries infected) and its disastrous effect on world economy (associated with limitations of human rights), speedy drug discovery is critical. In this situation, past investments into the development of new (animal-free) approach methods (NAM) for drug safety, efficacy, and quality evaluation can be leveraged. For this, we provide an overview of repurposing ideas to shortcut drug development times. Animal-based testing would be too lengthy, and it largely fails, when a pathogen is species-specific or if the desired drug is based on specific features of human biology. Fortunately, industry has already largely shifted to NAM, and some public funding programs have advanced the development of animal-free technologies. For instance, NAM can predict genotoxicity (a major aspect of carcinogenicity) within days, human antibodies targeting virus epitopes can be generated in molecular biology laboratories within weeks, and various human cell-based organoids are available to test virus infectivity and the biological processes controlling them. The European Medicines Agency (EMA) has formed an expert group to pave the way for the use of such approaches for accelerated drug development. This situation illustrates the importance of diversification in drug discovery strategies and clearly shows the shortcomings of an approach that invests 95% of resources into a single technology (animal experimentation) in the face of challenges that require alternative approaches.","Arch Toxicol","Busquet, Francois","Hartung, Thomas","Pallocca, Giorgia","Rovida, Costanza","Leist, Marcel","32447523"],"abstract":["The COVID-19-inducing virus, SARS-CoV2, is likely to remain a threat to human health unless efficient drugs or vaccines become available. Given the extent of the current pandemic (people in over one hundred countries infected) and its disastrous effect on world economy (associated with limitations of human rights), speedy drug discovery is critical. In this situation, past investments into the development of new (animal-free) approach methods (NAM) for drug safety, efficacy, and quality evaluation can be leveraged. For this, we provide an overview of repurposing ideas to shortcut drug development times. Animal-based testing would be too lengthy, and it largely fails, when a pathogen is species-specific or if the desired drug is based on specific features of human biology. Fortunately, industry has already largely shifted to NAM, and some public funding programs have advanced the development of animal-free technologies. For instance, NAM can predict genotoxicity (a major aspect of carcinogenicity) within days, human antibodies targeting virus epitopes can be generated in molecular biology laboratories within weeks, and various human cell-based organoids are available to test virus infectivity and the biological processes controlling them. The European Medicines Agency (EMA) has formed an expert group to pave the way for the use of such approaches for accelerated drug development. This situation illustrates the importance of diversification in drug discovery strategies and clearly shows the shortcomings of an approach that invests 95% of resources into a single technology (animal experimentation) in the face of challenges that require alternative approaches."],"journal":"Arch Toxicol","authors":["Busquet, Francois","Hartung, Thomas","Pallocca, Giorgia","Rovida, Costanza","Leist, Marcel"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447523","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00204-020-02787-2","topics":["Treatment"],"weight":1,"_version_":1667698385981800448,"score":9.490897,"similar":[{"pmid":32378471,"title":"Animal Models for Emerging Coronavirus: Progress and New Insights.","text":["Animal Models for Emerging Coronavirus: Progress and New Insights.","The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within recent two decades (SARS-CoV in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019). Much more serious than SARS-CoV in 2002, the current SARS-CoV-2 infection has been spreading to more than 213 countries, areas or territories and causing more than two million cases up to date (April 17, 2020). Unfortunately, no vaccine and specific anti-coronavirus drugs are available at present time. Current clinical treatment at hand is inadequate to suppress viral replication and inflammation, and reverse organ failure. Intensive research efforts have focused on increasing our understanding of viral biology of SARS-CoV-2, improving antiviral therapy and vaccination strategies. The animal models are important for both the fundamental research and drug discovery of coronavirus. This review aims to summarize the animal models currently available for SARS-CoV and MERS-CoV, and their potential use for the study of SARS-CoV-2. We will discuss the benefits and caveats of these animal models and present critical findings that might guide the fundamental studies and urgent treatment of SARS-CoV-2-caused diseases.","Emerg Microbes Infect","Yuan, Lunzhi","Tang, Qiyi","Cheng, Tong","Xia, Ningshao","32378471"],"abstract":["The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within recent two decades (SARS-CoV in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019). Much more serious than SARS-CoV in 2002, the current SARS-CoV-2 infection has been spreading to more than 213 countries, areas or territories and causing more than two million cases up to date (April 17, 2020). Unfortunately, no vaccine and specific anti-coronavirus drugs are available at present time. Current clinical treatment at hand is inadequate to suppress viral replication and inflammation, and reverse organ failure. Intensive research efforts have focused on increasing our understanding of viral biology of SARS-CoV-2, improving antiviral therapy and vaccination strategies. The animal models are important for both the fundamental research and drug discovery of coronavirus. This review aims to summarize the animal models currently available for SARS-CoV and MERS-CoV, and their potential use for the study of SARS-CoV-2. We will discuss the benefits and caveats of these animal models and present critical findings that might guide the fundamental studies and urgent treatment of SARS-CoV-2-caused diseases."],"journal":"Emerg Microbes Infect","authors":["Yuan, Lunzhi","Tang, Qiyi","Cheng, Tong","Xia, Ningshao"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378471","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/22221751.2020.1764871","keywords":["animal model","coronavirus","infectious disease","respiratory syndrome","vaccine and drug discovery"],"topics":["Treatment"],"weight":1,"_version_":1666597097458106368,"score":158.02849},{"pmid":32478897,"title":"Conditional Cell Reprogramming for Modeling Host-Virus Interactions and Human Viral Diseases.","text":["Conditional Cell Reprogramming for Modeling Host-Virus Interactions and Human Viral Diseases.","Conventional cancer and transformed cell lines are widely used in cancer biology and other fields within biology. These cells usually have abnormalities from the original tumor itself, but may also develop abnormalities due to genetic manipulation, or genetic and epigenetic changes during long term passages. Primary cultures may maintain lineage functions as the original tissue types, yet they have a very limited life span or population doubling time because of the nature of cellular senescence. Primary cultures usually have very low yields, and the high variability from any original tissue specimens, largely limiting their applications in research. Animal models are often used for studies of virus infections, disease modeling, development of antiviral drugs and vaccines. Human viruses often need a series of passages in vivo in order to adapt to the host environment because of variable receptors on the cell surface and may have intracellular restrictions from the cell types or host species. Here we describe a long term cell culture system, conditionally reprogrammed cells (CRCs), and its applications in modeling human viral diseases and drug discovery. Using feeder layer co-culture in presence of Y-27632 (conditional reprogramming, CR), CRCs can be obtained and rapidly propagated from surgical specimens, core or needle biopsies, and other minimally invasive or non-invasive specimens, for example, nasal cavity brushing. CRCs preserve their lineage functions, and provide biologically relevant and physiological conditions, which are suitable for studies of viral entry and replication, innate immune responses of host cells, and discovery of antiviral drugs. In this review, we summarize applications of CR technology in modeling host-virus interactions and human viral diseases, including SARS-CoV-2 and COVID-19, and anti-viral discovery. This article is protected by copyright. All rights reserved.","J Med Virol","Liu, Xuefeng","Mondal, Abdul M","32478897"],"abstract":["Conventional cancer and transformed cell lines are widely used in cancer biology and other fields within biology. These cells usually have abnormalities from the original tumor itself, but may also develop abnormalities due to genetic manipulation, or genetic and epigenetic changes during long term passages. Primary cultures may maintain lineage functions as the original tissue types, yet they have a very limited life span or population doubling time because of the nature of cellular senescence. Primary cultures usually have very low yields, and the high variability from any original tissue specimens, largely limiting their applications in research. Animal models are often used for studies of virus infections, disease modeling, development of antiviral drugs and vaccines. Human viruses often need a series of passages in vivo in order to adapt to the host environment because of variable receptors on the cell surface and may have intracellular restrictions from the cell types or host species. Here we describe a long term cell culture system, conditionally reprogrammed cells (CRCs), and its applications in modeling human viral diseases and drug discovery. Using feeder layer co-culture in presence of Y-27632 (conditional reprogramming, CR), CRCs can be obtained and rapidly propagated from surgical specimens, core or needle biopsies, and other minimally invasive or non-invasive specimens, for example, nasal cavity brushing. CRCs preserve their lineage functions, and provide biologically relevant and physiological conditions, which are suitable for studies of viral entry and replication, innate immune responses of host cells, and discovery of antiviral drugs. In this review, we summarize applications of CR technology in modeling host-virus interactions and human viral diseases, including SARS-CoV-2 and COVID-19, and anti-viral discovery. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Liu, Xuefeng","Mondal, Abdul M"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478897","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26093","keywords":["air-liquid interface (ali)","cell senescence","conditional reprogramming","emerging viruses","functional models","normal cells","organoids","physiological conditions"],"locations":["vivo"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668437835201380352,"score":153.0918},{"pmid":32186952,"pmcid":"PMC7103671","title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.","text":["COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics.","The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection.","Hum Vaccin Immunother","Dhama, Kuldeep","Sharun, Khan","Tiwari, Ruchi","Dadar, Maryam","Malik, Yashpal Singh","Singh, Karam Pal","Chaicumpa, Wanpen","32186952"],"abstract":["The novel coronavirus infection (COVID-19 or Coronavirus disease 2019) that emerged from Wuhan, Hubei province of China has spread to many countries worldwide. Efforts have been made to develop vaccines against human coronavirus (CoV) infections such as MERS and SARS in the past decades. However, to date, no licensed antiviral treatment or vaccine exists for MERS and SARS. Most of the efforts for developing CoV vaccines and drugs target the spike glycoprotein or S protein, the major inducer of neutralizing antibodies. Although a few candidates have shown efficacy in in vitro studies, not many have progressed to randomized animal or human trials, hence may have limited use to counter COVID-19 infection. This article highlights ongoing advances in designing vaccines and therapeutics to counter COVID-19 while also focusing on such experiences and advances as made with earlier SARS- and MERS-CoVs, which together could enable efforts to halt this emerging virus infection."],"journal":"Hum Vaccin Immunother","authors":["Dhama, Kuldeep","Sharun, Khan","Tiwari, Ruchi","Dadar, Maryam","Malik, Yashpal Singh","Singh, Karam Pal","Chaicumpa, Wanpen"],"date":"2020-03-19T11:00:00Z","year":2020,"_id":"32186952","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1080/21645515.2020.1735227","keywords":["covid-19","emerging coronavirus","drugs","therapeutics","vaccines"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138492524036096,"score":149.60008},{"pmid":32305589,"pmcid":"PMC7162749","title":"Combating Devastating COVID -19 by Drug Repurposing.","text":["Combating Devastating COVID -19 by Drug Repurposing.","Despite advances in Drug Discovery, the viral infections always remain the major challenge for the Scientists across the globe. The recent pandemic COVID-19 viral infection has created a disastrous situation all over the world. As no drug is available to treat such life- threatening disease and the mortality rate is significantly increased due to COVID-19; there is an utmost need to cure the infection by Drug Repurposing. Some counties are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data but they were found to be effective in some countries to treat affected COVID-19 patients (Off label/ Investigational). The article emphases the possible drug candidates in the treatment of COVID-19 infection. Most of these drugs were found to be effective in in vitro studies. There is a need to reassess the in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on the priority basis.","Int J Antimicrob Agents","Pawar, Ashish Yashwantrao","32305589"],"abstract":["Despite advances in Drug Discovery, the viral infections always remain the major challenge for the Scientists across the globe. The recent pandemic COVID-19 viral infection has created a disastrous situation all over the world. As no drug is available to treat such life- threatening disease and the mortality rate is significantly increased due to COVID-19; there is an utmost need to cure the infection by Drug Repurposing. Some counties are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data but they were found to be effective in some countries to treat affected COVID-19 patients (Off label/ Investigational). The article emphases the possible drug candidates in the treatment of COVID-19 infection. Most of these drugs were found to be effective in in vitro studies. There is a need to reassess the in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on the priority basis."],"journal":"Int J Antimicrob Agents","authors":["Pawar, Ashish Yashwantrao"],"date":"2020-04-20T11:00:00Z","year":2020,"_id":"32305589","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ijantimicag.2020.105984","keywords":["covid-19","corona virus","drug repurposing","sars-cov-2"],"locations":["Scientists"],"topics":["Treatment"],"weight":1,"_version_":1666138493396451328,"score":148.24927},{"pmid":32238094,"title":"Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach.","text":["Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach.","Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs (Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.Communicated by Ramaswamy H. Sarma.","J Biomol Struct Dyn","Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer","32238094"],"abstract":["Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs (Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.Communicated by Ramaswamy H. Sarma."],"journal":"J Biomol Struct Dyn","authors":["Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238094","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1080/07391102.2020.1751298","keywords":["3clpro","md simulation","sars-cov-2","corona virus","drug repurposing","remdesivir","virtual screening"],"locations":["Wuhan","China","Chymotrypsin","Chymotrypsin"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["remdesivir","flavone","Coumarins","Saquinavir","Darunavir"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490367115267,"score":145.39221}]}